The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer
Open accessAbstract
Purpose: To assess long-term outcomes of men with favorable-risk prostate cancer in a prospective, active-surveillance program. Methods: Curative intervention was recommended for disease reclassification to higher cancer grade or volume on prostate biopsy. Primary outcomes were overall, cancer-specific, and metastasis-free survival. Secondary outcomes were the cumulative incidence of reclassification and curative intervention. Factors associated with grade reclassification and curative intervention were evaluated in a Cox proportional hazards model. Results: A total of 1,298 men (median age, 66 years) with a median follow-up of 5 years (range, 0.01 to 18.00 years) contributed 6,766 person-years of follow-up since 1995. Overall, cancer-specific, and metastasis-free survival rates were 93%, 99.9%, and 99.4%, respectively, at 10 years and 69%, 99.9%, and 99.4%, respectively, at 15 years. The cumulative incidence of grade reclassification was 26% at 10 years and was 31% at 15 years; cumulative incidence of curative intervention was 50% at 10 years and was 57% at 15 years. The median treatment-free survival was 8.5 years (range, 0.01 to 18 years). Factors associated with grade reclassification were older age (hazard ratio [HR], 1.03 for each additional year; 95% CI, 1.01 to 1.06), prostate-specific antigen density (HR, 1.21 per 0.1 unit increase; 95% CI, 1.12 to 1.46), and greater number of positive biopsy cores (HR, 1.47 for each additional positive core; 95% CI, 1.26 to 1.69). Factors associated with intervention were prostate-specific antigen density (HR, 1.38 per 0.1 unit increase; 95% CI, 1.22 to 1.56) and a greater number of positive biopsy cores (HR, 1.35 for one additional positive core; 95% CI, 1.19 to 1.53). Conclusion: Men with favorable-risk prostate cancer should be informed of the low likelihood of harm from their diagnosis and should be encouraged to consider surveillance rather than curative intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,770
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60525-0 · Cited by 1,566
Early Detection of Prostate Cancer: AUA Guideline
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.119 · Cited by 1,242
Self-citationLong-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Klotz, L., Vesprini, D., Sethukavalan, P., Jethava, V., Zhang, L., Jain, S., Yamamoto, T., Mamedov, A., & Loblaw, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1192 · Cited by 1,221
20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen, P. C. (2005) · JAMA · doi:10.1001/jama.293.17.2095 · Cited by 1,187
Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0133 · Cited by 1,006
Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Garmo, H., Rider, J. R., Taari, K., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Spångberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311593 · Cited by 981
Prognostic G leason grade grouping: data based on the modified G leason scoring system
Pierorazio, P. M., Walsh, P. C., Partin, A. W., & Epstein, J. I. (2013) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11611.x · Cited by 751
Self-citationPredicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy
Eggener, S. E., Scardino, P. T., Walsh, P. C., Han, M., Partin, A. W., Trock, B. J., Feng, Z., Wood, D. P., Eastham, J. A., Yossepowitch, O., et al. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.10.057 · Cited by 640
Self-citationActive Surveillance for Prostate Cancer: A Systematic Review of the Literature
Dall’Era, M. A., Albertsen, P. C., Bangma, C., Carroll, P. R., Carter, H. B., Cooperberg, M. R., Freedland, S. J., Klotz, L. H., Parker, C., & Soloway, M. S. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.072 · Cited by 602
Self-citationTracking the clonal origin of lethal prostate cancer
Haffner, M. C., Mosbruger, T., Esopi, D. M., Fedor, H., Heaphy, C. M., Walker, D. A., Adejola, N., Gürel, M., Hicks, J., Meeker, A. K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70354 · Cited by 497
Screening for Prostate Cancer With the Prostate-Specific Antigen Test: A Review of Current Evidence
Hayes, J. H., & Barry, M. J. (2014) · JAMA · doi:10.1001/jama.2014.2085 · Cited by 361
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Motzer, R. J., Jonasch, E., Michaelson, M. D., Nandagopal, L., Gore, J. L., George, S., Alva, A., Haas, N., Harrison, M. R., Plimack, E. R., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0054 · Cited by 287
New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study
Zhao, Y. Y., Weir, M. A., Manno, M., Cordy, P., Gomes, T., Hackam, D. G., Juurlink, D. N., Mamdani, M., Moist, L., Parikh, C. R., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00401 · Cited by 258
Sundi, D., Ross, A. E., Humphreys, E. B., Han, M., Partin, A. W., Carter, H. B., & Schaeffer, E. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.0302 · Cited by 233
Self-citationPhysician Variation in Management of Low-Risk Prostate Cancer: A Population-Based Cohort Study
Hoffman, K. E., Niu, J., Shen, Y., Jiang, J., Davis, J. W., Kim, J., Kuban, D. A., Perkins, G. H., Shah, J. B., Smith, G. L., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3021 · Cited by 115
Newcomb, L. F., Brooks, J. D., Carroll, P. R., Feng, Z., Gleave, M. E., Nelson, P. S., Thompson, I. M., & Lin, D. W. (2009) · Urology · doi:10.1016/j.urology.2009.05.050 · Cited by 79
Cited by
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,640
The Diagnosis and Treatment of Prostate Cancer: A Review
Litwin, M. S., & Tan, H.-J. (2017) · JAMA · doi:10.1001/jama.2017.7248 · Cited by 1,435
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Wilt, T. J., Jones, K. M., Barry, M. J., Andriole, G. L., Culkin, D., Wheeler, T., Aronson, W. J., & Brawer, M. K. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615869 · Cited by 623
Tosoian, J. J., Mamawala, M., Epstein, J. I., Landis, P., Macura, K. J., Simopoulos, D. N., Carter, H. B., & Gorin, M. A. (2020) · European Urology · doi:10.1016/j.eururo.2019.12.017 · Cited by 259
Self-citation
Metadata
- Authors
- Tosoian, J. J., Mamawala, M., Epstein, J. I., Landis, P., Wolf, S., Trock, B. J., & Carter, H. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-10-20
- Volume
- 33
- Issue
- 30
- Pages
- 3379-3385
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140583819
- Cited by
- 555
- References
- 18
- FWCI
- 55.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.